[Clinical Significance of Multigene Assay in Papillary Thyroid Carcinoma]

To analyze the clinical significance of multigene assay in papillary thyroid carcinoma（PTC）. Patients who underwent thyroidectomy in a tertiary hospital from August 2021 to May 2022 were enrolled. The eight-gene panel was used to detect the tumor tissue of patients, and the correlation between gene mutations and clinical features was analyzed. Among 161 patients, mutation rate of V600E, 1 and promotor were 82.0%, 6.8% and 4.3%, respectively. V600E mutation was more common in male patients（=0.023）. promotor-mutated tumors had a large diameter（=0.019）, a high proportion of multifocal lesions（=0.050）, and a large number of lymph node metastases（=0.031）. Among 89 patients who completed preoperative detection, there was a strong consistency between the preoperative aspiration test and postoperative panel（Cohen κ=0.694, 95%: 0.482-0.906, <0.01）. In the hematoxylin-eosin sections obtained from 80 patients, V600E was still the main type of gene mutation, and the classical/follicular type was more distributed. promotor and 1 mutation were the main genetic events for tall-cell/columnar/hobnail type and diffuse sclerosing type, respectively. One-way ANOVA showed that there were differences in diagnosis age（=0.029） and tumor size（<0.01） among different pathological types. As a simple and feasible clinical detection method for PTC, the multigene assay can supplement the identification of important genetic events other than V600E, and provide more prognostic information and follow-up hints for postoperative patients.